This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

NextPaper Logo
nextpaper.ccCYBER CHRONICLE
RSS
EN中文

Full article

FULL TEXT

View this issue
HeadlineMEDTECH

Personalized Cancer Vaccine Platform ImmunoDesign FDA-Approved: From Tumor Biopsy to Custom Vaccine in Just 14 Days

The personalized cancer vaccine platform ImmunoDesign, jointly developed by BioNTech and Moderna, receives FDA approval, producing individualized mRNA vaccines from tumor biopsies in 14 days, with Phase III trials showing 65% reduction in melanoma recurrence.

A Custom Anti-Cancer Weapon for Every Patient

The FDA today formally approved personalized cancer vaccine platform ImmunoDesign — the world's first approved personalized mRNA cancer vaccine production platform, marking a historic shift from one-size-fits-all to individualized cancer treatment.

Developed jointly by Germany's BioNTech and America's Moderna, ImmunoDesign's workflow begins with whole-exome sequencing and transcriptome analysis of patient tumor tissue to identify tumor-specific mutant proteins (neoantigens). AI algorithms then select the 20-30 most immunogenic neoantigens from hundreds of candidates. Finally, mRNA sequences encoding these neoantigens are encapsulated in lipid nanoparticles to create the personalized vaccine.

The entire process takes just 14 days from tumor biopsy to finished vaccine. The vaccine is ready during post-surgical recovery for adjuvant therapy to prevent recurrence.

Phase III Clinical Data

The approval was based on a global Phase III trial enrolling 4,200 stage III-IV melanoma patients. The vaccine combined with immune checkpoint inhibitors achieved 78% 3-year recurrence-free survival versus 43% for checkpoint inhibitors alone — a 65% reduction in recurrence risk. Notably, 12% of vaccine patients showed complete response with no detectable residual tumors.

Expansion Plans

FDA-approved indication is stage III-IV melanoma adjuvant therapy. Phase III trials for non-small cell lung cancer, colorectal cancer, and pancreatic cancer are underway. Single treatment cost is $120,000 including sequencing, manufacturing, and first dose.